论文部分内容阅读
目的探讨CEA、CA125、CA153、Ferr、CA50五项血清肿瘤标志物联合检测对乳腺癌的辅助诊断价值。方法回顾性研究收集2013年6月1日至2015年12月31日由郑州人民医院确诊的93例乳腺癌(年龄31~78岁)、53例乳腺良性肿瘤患者(年龄33~62岁)和健康女性120例(年龄26~57岁)样本,检测CEA、CA125、CA153、Ferr和CA50的血清学水平,分析5项标志物在不同病理人群的水平差异,及单检和联检阳性检出率。采用SPSS 17.0单因素方差分析进行统计分析。结果乳腺癌患者血清CEA、CA125、CA15-3、Ferr和CA50的中位数水平分别为:2.81ng/ml、15.49U/ml、19.49U/ml、134.28ng/ml和12.70U/ml,四者均显著高于健康人组和良性病组的中位数水平(CEA:0.61ng/ml、1.07ng/ml;CA125:8.97U/ml、12.27U/ml;CA153:6.46U/ml、8.76U/ml;Ferr:33.16ng/ml、72.79ng/ml;CA50:6.91U/ml、9.04U/ml)(F值分别为8.867、6.982、24.486、35.550、16.145,P均<0.05)。单项指标中CA15-3的阳性检出率最高(35.48%);其次为Ferr(32.26%)。5项指标联合检测乳腺癌的阳性检出率最高(64.52%)。结论五项标志物联合检测诊断乳腺癌的敏感性优于单项指标,联合检测有助于乳腺癌的辅助诊断。
Objective To investigate the value of combined detection of five serum tumor markers CEA, CA125, CA153, Ferr and CA50 in the diagnosis of breast cancer. Methods A retrospective study was performed on 93 breast cancer patients (aged 31-78 years) and 53 benign breast tumors (aged 33-62 years) diagnosed by Zhengzhou People’s Hospital from June 1, 2013 to December 31, 2015 and Serum levels of CEA, CA125, CA153, Ferr and CA50 were detected in 120 healthy women (26-57 years old). The differences of five markers in different pathological groups were analyzed, and the positive detection rate . Statistical analysis was performed using SPSS 17.0 one-way ANOVA. Results The median serum levels of CEA, CA125, CA15-3, Ferr and CA50 in breast cancer patients were 2.81ng / ml, 15.49U / ml, 19.49U / ml, 134.28ng / ml and 12.70U / (CEA: 0.61 ng / ml, 1.07 ng / ml; CA125: 8.97 U / ml, 12.27 U / ml; CA153: 6.46 U / ml, 8.76 (F = 8.867, 6.982, 24.486, 35.550, and 16.145, P <0.05, respectively). The positive detection rate of CA15-3 in the single index was the highest (35.48%), followed by Ferr (32.26%). The detection rate of breast cancer with the five indexes was the highest (64.52%). Conclusions The sensitivity of the combined detection of five markers in the diagnosis of breast cancer is better than that of single indicators. Combined detection can be helpful in the diagnosis of breast cancer.